Short course showed no clear difference in hospitalization compared with long course treatment (low certainty).
Short course probably leads to higher bacteriuria compared with long course treatment (moderate certainty).
Short course showed no clear difference in fever compared with long course treatment (moderate certainty).
Short course showed no clear difference in UTI compared with long course treatment (moderate certainty).
Should short‐course antibiotic therapy showed no clear difference in mortality compared with prolonged‐course antibiotic therapy be used (moderate certainty).
Should short‐course antibiotic therapy showed no clear difference in mortality NF‐GNB compared with prolonged‐course antibiotic therapy be used (low certainty).
Should short‐course antibiotic therapy showed no clear difference in mortality MRSA compared with prolonged‐course antibiotic therapy be used (moderate certainty).
Should short‐course antibiotic therapy showed no clear difference in recurrence of pneumonia Clinical and/or microbiological criteria compared with prolonged‐course antibiotic therapy be used (low certainty).
Should short‐course antibiotic therapy probably leads to higher recurrence of pneumonia NF‐GNB Clinical and/or microbiological… compared with prolonged‐course antibiotic therapy be used (moderate certainty).
Should short‐course antibiotic therapy showed no clear difference in recurrence of pneumonia MRSA Clinical and/or microbiological criteria compared with prolonged‐course antibiotic therapy be used (moderate certainty).
Short‐course L‐AmB + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of L‐AmB + FLU (low certainty).
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes number of exacerbations(as reported by number of hospitalisations… compared with placebo (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes cure compared with daily anti‐TB regimens (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes death from any cause compared with daily anti‐TB regimens (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes relapse compared with daily anti‐TB regimens (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes adherence to treatment compared with daily anti‐TB regimens (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes treatment‐limiting adverse events compared with daily anti‐TB regimens (very low certainty).
Adults: higher dose/longer course showed no clear difference in re‐admission in compared with lower dose/shorter course (low certainty).